Definium Therapeutics, Inc. Cash Flow-to-Debt Ratio
Definium Therapeutics, Inc. cash flow-to-debt ratio. Definium Therapeutics, Inc. (DFTX) has a Cash Flow-to-Debt Ratio of -0.27x as of June 2026, meaning its operating cash flow of $-52.78 Million could theoretically repay 0% of its total liabilities ($194.22 Million) in one year. See how financially flexible is Definium Therapeutics, Inc. to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Definium Therapeutics, Inc. (2015–2025)
Cash flow-to-debt ratio of Definium Therapeutics, Inc. from 2015 to 2025. Historical debt coverage capacity for Definium Therapeutics, Inc. across 11 annual periods. Check Definium Therapeutics, Inc. (DFTX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Definium Therapeutics, Inc. Cash Flow-to-Debt Ratio by Year (2015–2025)
Definium Therapeutics, Inc. cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Definium Therapeutics, Inc.. For the full cash flow conversion analysis, see Definium Therapeutics, Inc. (DFTX) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.22x | $-131.56 Million | $107.77 Million | ▲ +6.4% |
| 2024 | -1.30x | $-79.13 Million | $60.70 Million | ▲ +6.0% |
| 2023 | -1.39x | $-64.36 Million | $46.41 Million | ▲ +47.2% |
| 2022 | -2.63x | $-50.14 Million | $19.08 Million | ▲ +29.2% |
| 2021 | -3.71x | $-45.82 Million | $12.34 Million | ▲ +11.1% |
| 2020 | -4.18x | $-23.60 Million | $5.65 Million | ▼ -299.2% |
| 2019 | -1.05x | $-208.12K | $198.96K | ▲ +98.8% |
| 2018 | -87.79x | $-722.45K | $8.23K | ▼ -960.4% |
| 2017 | -8.28x | $-665.98K | $80.44K | ▼ -2245.8% |
| 2016 | -0.35x | $-26.64K | $75.47K | ▲ +94.3% |
| 2015 | -6.22x | $-46.56K | $7.49K | — |